| For: | Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World J Gastroenterol 2021; 27(39): 6527-6550 [PMID: 34754151 DOI: 10.3748/wjg.v27.i39.6527] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i39/6527.htm |
| Number | Citing Articles |
| 1 |
Dandan Gu, Shaoyang Huang, Kai Zhao, Xiaohong Zhang, Jinjing Zhang, Wei Xiong. Global trends in resistance studies of gemcitabine and pancreatic cancer: a bibliometric and visual analysis from 2010 to 2024. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1564561
|
| 2 |
Zhefang Wang, Zicheng Lyu, Raphael Palmen, Qi Bao, Felix Popp, Qiongzhu Dong, Christiane J. Bruns, Yue Zhao. Mitophagy in pancreatic cancer: mechanistic insights and implications for novel therapeutic strategies. Cell Death Discovery 2026; 12(1) doi: 10.1038/s41420-026-02948-9
|
| 3 |
Yanjie Cao, Dedong Yu, Yun Wu, Wei Zhu. Regional intra-arterial vs. systemic chemotherapy for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1197424
|
| 4 |
Mengxin Li, Xuanzhong Wang, Xuyang Chen, Jinghui Hong, Ye Du, Dong Song. GK921, a transglutaminase inhibitor, strengthens the antitumor effect of cisplatin on pancreatic cancer cells by inhibiting epithelial-to-mesenchymal transition. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2024; 1870(2) doi: 10.1016/j.bbadis.2023.166925
|
| 5 |
Negar Jamshidi, Amir Modarresi Chahardehi, Nazanin Jamshidi, Mahta Chehresaz, Farzaneh Tafvizi, Jalal Ranjbar, Vahid Chaleshi, Hamid Asadzadeh Aghdaei.
Exploring the synergistic therapeutic potential of green-synthesized silver nanoparticles by
Urtica dioica
in combination with gemcitabine on pancreatic cancer cells
. Inorganic and Nano-Metal Chemistry 2026; 56(7) doi: 10.1080/24701556.2026.2648645
|
| 6 |
Xinxing Wang, Wei Su, Chuan Qin, Ruxin Gao, Shuai Shao, Xianwen Xu, Zhenhai Zhang, Junlin Gao. Knockdown of TGF-β in Pancreatic Cancer Helps Ameliorate Gemcitabine Resistance. Frontiers in Bioscience-Landmark 2024; 29(7) doi: 10.31083/j.fbl2907269
|
| 7 |
Tianxing Zhou, Yongjie Xie, Xupeng Hou, Weiwei Bai, Xueyang Li, Ziyun Liu, Quan Man, Jingyan Sun, Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yifei Wang, Hongwei Wang, Wenna Jiang, Song Gao, Tiansuo Zhao, Antao Chang, Xiuchao Wang, Hongxia Sun, Xiufeng Zhang, Shengyu Yang, Chongbiao Huang, Jihui Hao, Jing Liu. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Journal of Experimental & Clinical Cancer Research 2023; 42(1) doi: 10.1186/s13046-023-02671-8
|
| 8 |
Jianbiao Xu, Hong Yao, Junfeng Wang, Yun Jin, Wei Chang, Lanjiang Li, Lei Zou. Perineural invasion and the “cold” tumor microenvironment in pancreatic cancer: mechanisms of crosstalk and therapeutic opportunities. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1650117
|
| 9 |
Ning Xia, Nannan Yang, Qungang Shan, Ziyin Wang, Xiaoyu Liu, Yingjie Chen, Jian Lu, Wei Huang, Zhongmin Wang. HNRNPC regulates RhoA to induce DNA damage repair and cancer‐associated fibroblast activation causing radiation resistance in pancreatic cancer. Journal of Cellular and Molecular Medicine 2022; 26(8) doi: 10.1111/jcmm.17254
|
| 10 |
Inês Mendes, Lara Marques, Eduarda Ribeiro, Nuno Vale. Repurposing Clotrimazole for Pancreatic Ductal Adenocarcinoma: Comparative In Vitro Evaluation and In Silico ADMET Context. Physchem 2026; 6(1) doi: 10.3390/physchem6010017
|
| 11 |
Sohum Patel, Eleanor Jenkins, Rutuj P Kusurkar, Sherry Lee, Wei Jiang, Avinoam Nevler, Matthew McCoy, Michael J Pishvaian, Rosalie C Sears, Jonathan R Brody, Charles J Yeo, Aditi Jain. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Neoplasia 2025; 63 doi: 10.1016/j.neo.2025.101152
|
| 12 |
Ju-Hee Park, Do-Yeon Kim, Han-Heom Na, Tae-Hyung Kwon, Jin-Sung Park, Young Taek Oh, Keun-Cheol Kim. Cannabigerol induces endoplasmic reticulum stress-mediated apoptosis and ferroptosis via the IRE1α-XBP1 axis in human pancreatic cancer cells. Free Radical Biology and Medicine 2026; 250 doi: 10.1016/j.freeradbiomed.2026.03.051
|
| 13 |
Wei Hu, Mingxu Li, Yan Wang, Chengcheng Zhong, Xinxin Si, Xiao Shi, Zhong Wang. Comprehensive bioinformatics analysis reveals the significance of forkhead box family members in pancreatic adenocarcinoma. Aging 2023; 15(1) doi: 10.18632/aging.204455
|
| 14 |
Shwetapadma Dash, Sonali Sahoo, Sanjeeb Kumar Sahoo. Recent Advances in Nanocarriers for Pancreatic Cancer Therapy. 2024; doi: 10.1016/B978-0-443-19142-8.00017-6
|
| 15 |
Sreejith Thrivikraman Nair, C Abhi, Kaladhar Kamalasanan, K. Pavithran, Ashok R. Unni, MS Sithara, Manjit Sarma, T S Mangalanandan. Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer. Molecular Pharmaceutics 2024; 21(12) doi: 10.1021/acs.molpharmaceut.4c00801
|
| 16 |
Emily A. Godfrey, Soo Jeon Choi, Michael Sestito, Tracy W. Liu, Slawomir Lukomski, Brian A. Boone. Application of group A streptococcal collagen-like protein 1-expressing Lactococcus as a novel immunotherapeutic against pancreatic ductal adenocarcinoma. Scientific Reports 2026; 16(1) doi: 10.1038/s41598-026-36657-1
|
| 17 |
Kohei Yamakawa, Michiyo Koyanagi-Aoi, Akihito Machinaga, Nobuyuki Kakiuchi, Tomonori Hirano, Yuzo Kodama, Takashi Aoi. Blockage of retinoic acid signaling via RARγ suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase. Cancer Cell International 2023; 23(1) doi: 10.1186/s12935-023-02928-4
|
| 18 |
Jinping Zhang, Shuman Zhang, Isabella Dörflein, Xiaofan Ren, Susanne Pfeffer, Nathalie Britzen-Laurent, Robert Grützmann, Xianglong Duan, Christian Pilarsky. Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. Cancers 2023; 15(19) doi: 10.3390/cancers15194842
|
| 19 |
Congyuan Zhu, Hao Hu, Ye Ma, Shuming Xiong, Dongming Zhu. Vav1‐dependent Rac1 activation mediates hypoxia‐induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF‐1α expression. Cell Biology International 2023; 47(11) doi: 10.1002/cbin.12074
|
| 20 |
Frederik J. Hansen, Anke Mittelstädt, Finn-Niklas Clausen, Samuel Knoedler, Leonard Knoedler, Sebastian Klöckner, Isabelle Kuchenreuther, Johanne Mazurie, Lisa-Sophie Arnold, Anna Anthuber, Anne Jacobsen, Susanne Merkel, Nadine Weisel, Bettina Klösch, Alara Karabiber, Irem Tacyildiz, Franziska Czubayko, Helena Reitberger, Amr El Gendy, Maximilian Brunner, Christian Krautz, Kerstin Wolff, Sidonia Mihai, Clemens Neufert, Jürgen Siebler, Robert Grützmann, Georg F. Weber, Paul David. CD71 expressing circulating neutrophils serve as a novel prognostic biomarker for metastatic spread and reduced outcome in pancreatic ductal adenocarcinoma patients. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-70916-3
|
| 21 |
Carmen Mota Reyes, Helmut Friess, Ihsan Ekin Demir. Neural crossroads of pancreatic cancer: how nociceptors drive tumor progression and immune evasion. Cell Research 2025; 35(6) doi: 10.1038/s41422-025-01124-5
|
| 22 |
Olivia M. Smith, Nicole Lintern, Jiahao Tian, Bárbara M. Mesquita, Sabrina Oliveira, Veronika Vymetalkova, Jai Prakash, Andrew M. Smith, David G. Jayne, Michal Heger, Yazan S. Khaled. Biomimetic Tumour Model Systems for Pancreatic Ductal Adenocarcinoma in Relation to Photodynamic Therapy. International Journal of Molecular Sciences 2025; 26(13) doi: 10.3390/ijms26136388
|
| 23 |
Hajime Nakamura, Megumi Watanabe, Kohichi Takada, Tatsuya Sato, Fumihito Hikage, Araya Umetsu, Joji Muramatsu, Masato Furuhashi, Hiroshi Ohguro. Modulation of Epithelial–Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel. Biomedicines 2024; 12(5) doi: 10.3390/biomedicines12051011
|
| 24 |
Shilong Han, Chuanwu Cao, Rui Liu, YiFeng Yuan, Long Pan, Minjie Xu, Chao Hu, Xiaojun Zhang, Maoquan Li, Xiaoping Zhang. GAS41 mediates proliferation and GEM chemoresistance via H2A.Z.2 and Notch1 in pancreatic cancer. Cellular Oncology 2022; 45(3) doi: 10.1007/s13402-022-00675-8
|
| 25 |
Erika Stefàno, Gianluca Rovito, Luca G. Cossa, Federica De Castro, Viviana Vergaro, Asjad Ali, Giulia My, Danilo Migoni, Antonella Muscella, Santo Marsigliante, Michele Benedetti, Francesco Paolo Fanizzi, Massimiliano F. Peana. Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells. Bioinorganic Chemistry and Applications 2024; 2024(1) doi: 10.1155/bca/5588491
|
| 26 |
Hai Yang, Bin Liu, Dongxue Liu, Zhirong Yang, Shuman Zhang, Pengyan Xu, Yuming Xing, Isabella Kutschick, Susanne Pfeffer, Nathalie Britzen-Laurent, Robert Grützmann, Christian Pilarsky. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Cancers 2022; 14(13) doi: 10.3390/cancers14133152
|
| 27 |
Thierry Voisin, Pascal Nicole, Valérie Gratio, Anaïs Chassac, Dounia Mansour, Vinciane Rebours, Anne Couvelard, Alain Couvineau. The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.904327
|
| 28 |
Alessandro Gregori, Cecilia Bergonzini, Mjriam Capula, Rick Rodrigues de Mercado, Erik H. J. Danen, Elisa Giovannetti, Thomas Schmidt. Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel. Cancers 2024; 16(22) doi: 10.3390/cancers16223863
|
| 29 |
Mirco Masi, Laura Poppi, Viola Previtali, Shannon R. Nelson, Kieran Wynne, Giulia Varignani, Federico Falchi, Marina Veronesi, Ennio Albanesi, Daniele Tedesco, Francesca De Franco, Andrea Ciamarone, Samuel H. Myers, Jose Antonio Ortega, Greta Bagnolini, Giovanni Ferrandi, Fulvia Farabegoli, Nicola Tirelli, Giuseppina Di Stefano, Giorgio Oliviero, Naomi Walsh, Marinella Roberti, Stefania Girotto, Andrea Cavalli. Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity. Cell Death Discovery 2025; 11(1) doi: 10.1038/s41420-025-02382-3
|
| 30 |
Agnieszka Kurdyn, Ewa Paluszkiewicz, Ewa Augustin. Pro-Apoptotic Effects of Unsymmetrical Bisacridines in 3D Pancreatic Multicellular Tumor Spheroids. International Journal of Molecular Sciences 2025; 26(15) doi: 10.3390/ijms26157557
|
| 31 |
Aarfa Queen, Humaira Naaz Bhutto, Mohd Yousuf, Mansoor Ali Syed, Md. Imtaiyaz Hassan. Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation. Seminars in Cancer Biology 2022; 86 doi: 10.1016/j.semcancer.2022.01.001
|
| 32 |
Jinsheng Ding, Yongjie Xie, Ziyun Liu, Zhaoyu Zhang, Bo Ni, Jingrui Yan, Tianxing Zhou, Jihui Hao. Hypoxic and Acidic Tumor Microenvironment–Driven AVL9 Promotes Chemoresistance of Pancreatic Ductal Adenocarcinoma via the AVL9-IκBα-SKP1 Complex. Gastroenterology 2025; 168(3) doi: 10.1053/j.gastro.2024.10.042
|
| 33 |
Hitoshi Masuo, Koji Kubota, Akira Shimizu, Tsuyoshi Notake, Satoru Miyazaki, Takahiro Yoshizawa, Hiroki Sakai, Hikaru Hayashi, Yuji Soejima. Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines. Cancer Science 2023; 114(11) doi: 10.1111/cas.15962
|
| 34 |
Kaidong Liu, Yiding Geng, Linzhu Wang, Huanhuan Xu, Min Zou, Yawei Li, Zhangxiang Zhao, Tingting Chen, Fengyan Xu, Liang Sun, Shuliang Wu, Yunyan Gu. Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma. Molecular Oncology 2022; 16(16) doi: 10.1002/1878-0261.13279
|
| 35 |
Sunisa Prasopporn, Orawan Suppramote, Ben Ponvilawan, Chanette Jamyuang, Jantappapa Chanthercrob, Amphun Chaiboonchoe, Pimkanya More-Krong, Kamonchanok Kongsri, Monthira Suntiparpluacha, Rawisak Chanwat, Krittiya Korphaisarn, Seiji Okada, Somponnat Sampattavanich, Siwanon Jirawatnotai. Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1021632
|
| 36 |
Zhefang Wang, Qiu Huang, Jiangang Zhao, Zicheng Lyu, Feng Ju, Bo You, Jie Wang, Qiongzhu Dong, Margarete Odenthal, Alexander Quaas, Kalliope N. Diakopoulos, Hana Algül, Maximilian Reichert, Christiane J. Bruns, Yue Zhao. LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming. Cell Death & Disease 2026; 17(1) doi: 10.1038/s41419-026-09075-4
|
| 37 |
Sheng‐Yi Chen, Yi‐Hao Hsu, Sheng‐Yang Wang, Ying‐Yin Chen, Cheng‐Jie Hong, Gow‐Chin Yen. Lucidone inhibits autophagy and MDR1 via HMGB1/RAGE/PI3K/Akt signaling pathway in pancreatic cancer cells. Phytotherapy Research 2022; 36(4) doi: 10.1002/ptr.7385
|
| 38 |
Ryan Sasse. A hypothetical dual pH-sensitive nanoparticle strategy for enhanced drug delivery in pancreatic ductal adenocarcinoma. Medical Hypotheses 2025; 198 doi: 10.1016/j.mehy.2025.111634
|
| 39 |
Sara Noorani, Rían Ó Madáin, Jojanneke Stoof, Elodie Lepeltier, Esen Efeoglu, Michael Henry, Paula Meleady, Tia E. Keyes, Naomi Walsh. Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer. Biomedicine & Pharmacotherapy 2026; 198 doi: 10.1016/j.biopha.2026.119273
|
| 40 |
D. Quatannens, Y. Verhoeven, S. van der Heijden, D. Peeters, J. Claes, C. Hermans, H. Lambrechts, K. Zwaenepoel, P. van Dam, M. Peeters, H. Prenen, S. Koljenovic, J. De Waele, C. Faes, F. Lardon, G. Roeyen, E. Smits, J. Van Audenaerde. Protein-level profiling of TIGIT axis components in human PDAC reveals immune–suppressive expression patterns. Cancer Immunology, Immunotherapy 2026; 75(4) doi: 10.1007/s00262-026-04343-w
|
| 41 |
Fei Hou, Xu Zhou, Yu-e Huang, Haizhou Liu, Mengqin Yuan, Jiahao Chen, Quan Wang, Wei Jiang. Characterization and clinical implications of CpG island methylator phenotypes of resistant tumors. Clinical Epigenetics 2026; 18(1) doi: 10.1186/s13148-026-02058-4
|
| 42 |
|
| 43 |
Yunguang Li, Shijie Tang, Xiaohan Shi, Jingwen Lv, Xueyuan Wu, Yehan Zhang, Huan Wang, Juan He, Yiqin Zhu, Yi Ju, Yajuan Zhang, Shiwei Guo, Weiwei Yang, Huiyong Yin, Luonan Chen, Dong Gao, Gang Jin. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Reports Medicine 2023; 4(9) doi: 10.1016/j.xcrm.2023.101162
|
| 44 |
Sae Hamaya, Kyoko Oura, Asahiro Morishita, Tsutomu Masaki. Cisplatin in Liver Cancer Therapy. International Journal of Molecular Sciences 2023; 24(13) doi: 10.3390/ijms241310858
|
| 45 |
Rangaraj Kaviyaprabha, Thandaserry Vasudevan Miji, Puthupparambil Shaji Sreelakshmi, Sridhar Muthusami, Palanisamy Arulselvan, Muruganantham Bharathi. Unveiling the Potential Role of Hesperetin and Emodin as a Combination Therapy to Inhibit the Pancreatic Cancer Progression against the C-Met Gene. Protein & Peptide Letters 2025; 32(4) doi: 10.2174/0109298665363165250225100109
|
| 46 |
Mengting Chen, Xiaoyu Sun, Yongjiang He, Shangjun Li, Chunyan Liu, Zehua Liao, Zhiyu Zhu, Jie Gu, Jing Xia, Peiyu Yan, Yiping Mou, Xueni Sun, Xinbing Sui. Butein suppresses pancreatic cancer progression by downregulating CDK2 and disrupting CDK2/CyclinA2 interaction. Biochemical Pharmacology 2026; 251 doi: 10.1016/j.bcp.2026.118099
|
| 47 |
Moises O. Guardado Rivas, Shawn D. Stuart, Daniel Thach, Michael Dahan, Robert Shorr, Zuzana Zachar, Paul M. Bingham, Debabrata Banerjee. Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613. PLOS ONE 2022; 17(6) doi: 10.1371/journal.pone.0269620
|
| 48 |
Rui Wang, Haoda Chen, Bowen Huang, Yanru Feng, Wentao Zhong, Weiwei Li, Xinmo Fu, Anqi Qin, Min Yu, Ji Zhu, Weifeng Hong. YY1-mediated expansion of SLC2A1+ ductal cells drives aging-associated EMT and metastatic potential in pancreatic ductal adenocarcinoma. Genes & Diseases 2026; doi: 10.1016/j.gendis.2026.102248
|
| 49 |
Ingrid Garajová, Marianna Peroni, Fabio Gelsomino, Francesco Leonardi. A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists. Current Oncology 2023; 30(11) doi: 10.3390/curroncol30110694
|
| 50 |
Zhihao Zhao, Yutong Yang, Liu Zhang, Xu He, Kaiyue Ding, Yingting Chen, Yuexue Huo, Peiyu Li, Ruotong Li, Tanveer Ali, Danping Zhao, Hyokchol Choe, Junnan Ma, Dong Shang, Lin Zhang. Multi-omics and network pharmacology reveal the mechanisms of Scutellaria barbata D.Don and Scleromitrion diffusum (Willd.) R.J.Wang against pancreatic cancer. Scientific Reports 2026; 16(1) doi: 10.1038/s41598-026-45676-x
|
| 51 |
Meiqi Ren, Zhichao(Eric) Ai, Yan Zhang, Linghong Shi, Yafei Liu, Haixia Liu, Hong Shen, Xiangyu Yao, Zhipeng Yan. cGAS-STING signaling in the tumor microenvironment induces myeloid cell activation and favors T cell-mediated antitumor immunity. Cancer Biology & Therapy 2025; 26(1) doi: 10.1080/15384047.2025.2585562
|